BL-B01D1 does not target DNA topoisomerase I on cell surfaces; it binds EGFR/HER3, is internalized, and releases brengitecan, which inhibits topoisomerase I to cause DNA damage and apoptosis. Any killing of topoisomerase I–expressing cells occurs only secondarily (e.g., bystander diffusion) rather than by direct targeting of this antigen.